Jesmond Dalli Selected Research

5S,12R,18R- trihydroxy- 6Z,8E,10E,14Z,16E- eicosapentaenoic acid

1/2020	RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance.
11/2019	Proresolving Mediators LXB4 and RvE1 Regulate Inflammation in Stromal Cells from Patients with Shoulder Tendon Tears.
10/2018	ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages.
1/2018	Resolvins suppress tumor growth and enhance cancer therapy.
1/2017	Neutrophil Resolvin E1 Receptor Expression and Function in Type 2 Diabetes.
1/2017	Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jesmond Dalli Research Topics

Disease

94	Inflammation (Inflammations) 05/2022 - 06/2007
13	Infections 01/2020 - 01/2014
7	Peritonitis 01/2022 - 07/2010
7	Sepsis (Septicemia) 01/2020 - 01/2013
6	Obesity 01/2021 - 09/2012
5	Arthritis (Polyarthritis) 01/2020 - 01/2016
3	Blister (Bulla) 01/2022 - 08/2013
3	Rheumatoid Arthritis 10/2020 - 11/2012
3	Ischemia 11/2017 - 03/2010
3	Edema (Dropsy) 01/2016 - 03/2010
3	Pneumonia (Pneumonitis) 09/2015 - 11/2014
2	Epilepsy (Aura) 01/2022 - 11/2018
2	Seizures (Absence Seizure) 01/2022 - 11/2018
2	Atherosclerosis 01/2022 - 10/2018
2	Endotoxemia 01/2021 - 01/2018
2	Critical Illness (Critically Ill) 01/2021 - 01/2017
2	Wounds and Injuries (Trauma) 01/2021 - 12/2017
2	Neuroinflammatory Diseases 01/2021 - 11/2018
2	Hypoxia (Hypoxemia) 11/2020 - 01/2020
2	Atherosclerotic Plaque (Atheroma) 11/2020 - 10/2018
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 01/2017
2	Fibrosis (Cirrhosis) 01/2020 - 07/2015
2	Tuberculosis (Tuberculoses) 01/2020 - 01/2014
2	Colitis 01/2020 - 11/2017
2	Brain Infarction 11/2019 - 01/2018
2	Tendinopathy (Tendonitis) 01/2019 - 01/2017
2	Infarction (Infarctions) 01/2018 - 01/2017
2	Neoplasms (Cancer) 01/2018 - 01/2015
2	Reperfusion Injury 01/2017 - 05/2015
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2017 - 11/2014
2	Cognitive Dysfunction 01/2016 - 01/2015
2	Chronic Obstructive Pulmonary Disease (COPD) 10/2015 - 09/2012
2	Pain (Aches) 04/2015 - 04/2012
1	Skin Diseases (Skin Disease) 01/2022
1	HIV Infections (HIV Infection) 01/2022
1	Neurogenic Inflammation 01/2022

Drug/Important Bio-Agent (IBA)

54	LipidsIBA 01/2022 - 11/2012
11	resolvin D1IBA 01/2022 - 08/2012
7	AutacoidsIBA 05/2022 - 01/2013
7	LipoxinsIBA 01/2022 - 03/2010
7	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 01/2020 - 02/2013
6	Essential Fatty AcidsIBA 01/2022 - 01/2016
6	AcidsIBA 06/2021 - 01/2013
6	EicosanoidsIBA 06/2021 - 09/2013
6	5S,12R,18R- trihydroxy- 6Z,8E,10E,14Z,16E- eicosapentaenoic acidIBA 01/2020 - 01/2017
6	Docosahexaenoic AcidsIBA 01/2020 - 08/2012
5	ZymosanIBA 01/2022 - 07/2010
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 02/2013
5	lipoxin A4IBA 01/2022 - 07/2015
5	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2019
5	Leukotriene B4IBA 01/2020 - 09/2015
5	Biological ProductsIBA 11/2019 - 01/2017
5	Peptides (Polypeptides)IBA 01/2017 - 06/2007
5	ProstaglandinsIBA 01/2017 - 10/2014
5	7,14- dihydroxydocosa- 4,8,10,12,16,19- hexaenoic acidIBA 12/2016 - 04/2012
5	Annexin A1IBA 01/2012 - 01/2009
4	LigandsIBA 01/2022 - 03/2010
4	CytokinesIBA 01/2018 - 10/2015
4	Carbon MonoxideIBA 12/2016 - 06/2013
3	docosapentaenoic acidIBA 01/2022 - 11/2018
3	protectin D1IBA 01/2022 - 01/2017
3	lipoxin B4IBA 01/2022 - 01/2017
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2020 - 03/2010
3	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 08/2019 - 12/2015
3	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2019 - 10/2012
3	EnzymesIBA 01/2019 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 08/2013 - 11/2010
2	Arachidonic Acid (Vitamin F)IBA 01/2022 - 01/2019
2	Cantharidin (Cantharides)IBA 01/2022 - 01/2017
2	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2022 - 01/2018
2	Interleukin-4 (Interleukin 4)IBA 10/2021 - 01/2020
2	resolvin D5IBA 01/2020 - 01/2017
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 12/2017
2	AlbuminsIBA 01/2020 - 01/2018
2	Dinoprostone (PGE2)FDA Link 01/2020 - 01/2017
2	Dihydrotachysterol (AT 10)IBA 01/2020 - 01/2014
2	Interleukin-6 (Interleukin 6)IBA 11/2019 - 01/2013
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2019 - 01/2017
2	Eicosapentaenoic AcidIBA 01/2019 - 09/2015
2	Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA 10/2018 - 11/2017
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2018 - 04/2015
2	CD59 AntigensIBA 11/2017 - 04/2016
2	Atorvastatin (Lipitor)FDA Link 01/2017 - 09/2015
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 01/2014
2	resolvin D2IBA 01/2017 - 07/2015
2	Amyloid (Amyloid Fibrils)IBA 01/2016 - 01/2015
2	SmokeIBA 10/2015 - 09/2012
2	MicroRNAs (MicroRNA)IBA 11/2013 - 01/2012
2	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 03/2010 - 01/2009
1	12-Hydroxy-5,8,10,14-eicosatetraenoic AcidIBA 01/2022
1	Transient Receptor Potential ChannelsIBA 01/2022
1	IntegrinsIBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 01/2022
1	NeuropeptidesIBA 01/2022

Therapy/Procedure

13	Therapeutics 01/2022 - 01/2013
2	Resuscitation 01/2021 - 01/2020
2	Punctures 01/2020 - 12/2016
2	Ligation 01/2020 - 12/2016
2	Drug Therapy (Chemotherapy) 01/2018 - 04/2012
2	Vagotomy 01/2017 - 06/2014